1.Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities.
Seo Yun KIM ; Sang Min LEE ; Jae Joon YIM ; Chul Gyu YOO ; Young Whan KIM ; Sung Koo HAN ; Seok Chul YANG
Yonsei Medical Journal 2013;54(5):1227-1233
PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9+/-3.3 months in the comorbidity group and 9.3+/-3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients.
Age Factors
;
Aged
;
Aged, 80 and over
;
Antitubercular Agents/adverse effects/*therapeutic use
;
Comorbidity
;
Female
;
Humans
;
*Immunocompromised Host
;
Isoniazid/adverse effects/*therapeutic use
;
Male
;
Retrospective Studies
;
Rifampin/adverse effects/*therapeutic use
;
Risk Factors
;
Treatment Outcome
;
Tuberculosis/*drug therapy/epidemiology/immunology
2.Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels.
Ina JEONG ; Jong Sun PARK ; Young Jae CHO ; Ho Il YOON ; Junghan SONG ; Choon Taek LEE ; Jae Ho LEE
Journal of Korean Medical Science 2015;30(2):167-172
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Alanine Transaminase/blood
;
Antitubercular Agents/adverse effects/*blood/therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug-Induced Liver Injury/*blood
;
Ethambutol/adverse effects/blood/therapeutic use
;
Female
;
Humans
;
Isoniazid/adverse effects/blood/therapeutic use
;
Liver/*pathology
;
Liver Function Tests
;
Male
;
Middle Aged
;
Pyrazinamide/adverse effects/blood/therapeutic use
;
Retrospective Studies
;
Rifampin/adverse effects/blood/therapeutic use
;
Tuberculosis, Pulmonary/drug therapy
;
Young Adult
3.Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels.
Ina JEONG ; Jong Sun PARK ; Young Jae CHO ; Ho Il YOON ; Junghan SONG ; Choon Taek LEE ; Jae Ho LEE
Journal of Korean Medical Science 2015;30(2):167-172
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Alanine Transaminase/blood
;
Antitubercular Agents/adverse effects/*blood/therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug-Induced Liver Injury/*blood
;
Ethambutol/adverse effects/blood/therapeutic use
;
Female
;
Humans
;
Isoniazid/adverse effects/blood/therapeutic use
;
Liver/*pathology
;
Liver Function Tests
;
Male
;
Middle Aged
;
Pyrazinamide/adverse effects/blood/therapeutic use
;
Retrospective Studies
;
Rifampin/adverse effects/blood/therapeutic use
;
Tuberculosis, Pulmonary/drug therapy
;
Young Adult
4.Scanning laser polarimetry in pulmonary tuberculosis patients on chemotherapy.
Wilson W T TANG ; Jimmy S M LAI ; Clement C Y THAM ; Kam-Keung CHAN ; Kin-Sang CHAN
Annals of the Academy of Medicine, Singapore 2006;35(6):395-399
INTRODUCTIONThe aim of this study was to analyse the thickness of the retinal nerve fibre layer (RNFL) of pulmonary tuberculosis patients on ethambutol and isoniazid.
MATERIALS AND METHODSThis was a prospective cohort study where patients with newly diagnosed pulmonary tuberculosis requiring chemotherapy, including ethambutol and isoniazid, were imaged using scanning laser polarimetry. Their mean baseline RNFL thickness and various scanning laser polarimetry parameters of both eyes were measured 2 weeks after the commencement of chemotherapy. The measurements were repeated at 3 months and 6 months after treatment. The various parameters of the baseline and the follow-up measurements were compared using paired sample t-test with Bonferroni correction.
RESULTSTwenty-four patients (16 males and 8 females; mean age, 51.0 +/- 17.6 years) were recruited. There was no statistically significant difference between the baseline and the follow-up measurements in RNFL thickness and all other scanning laser polarimetry parameters.
CONCLUSIONIn this cohort of subjects, there was no subclinical change in RNFL thickness detected by scanning laser polarimetry in pulmonary tuberculosis patients on chemotherapy, including ethambutol and isoniazid, after 6 months of treatment.
Adult ; Aged ; Aged, 80 and over ; Antitubercular Agents ; adverse effects ; therapeutic use ; Diagnostic Techniques, Ophthalmological ; Ethambutol ; adverse effects ; therapeutic use ; Female ; Humans ; Isoniazid ; adverse effects ; therapeutic use ; Lasers ; Male ; Middle Aged ; Prospective Studies ; Retinal Diseases ; chemically induced ; diagnosis ; Tuberculosis, Pulmonary ; drug therapy